Quadruple-drug SPC therapy achieved target BP in 73.15%, target LDL-C in 71.11%, and both targets in 57.11% after 12 weeks with low adverse events.
Does a quadruple-drug fixed-dose single-pill combination of losartan, amlodipine, rosuvastatin, and ezetimibe improve the achievement of target blood pressure and LDL-C levels in patients with hypertension and dyslipidemia?
A quadruple-drug single-pill combination of losartan, amlodipine, rosuvastatin, and ezetimibe is highly effective and safe for simultaneously achieving blood pressure and LDL-C targets in patients with hypertension and dyslipidemia.
Absolute Event Rate: 0% vs 0%
Abstract Background Single-pill combination (SPC) therapy can reduce the pill burden in patients with hypertension and dyslipidemia, potentially improving medication adherence and clinical outcomes. Purpose This study aimed to evaluate the efficacy and safety of a quadruple-drug fixed-dose SPC (QFDC) therapy combining losartan, amlodipine, rosuvastatin, and ezetimibe (L/A/R/E) in these patients. Methods Between September 2021 and September 2023, a total of 2,150 patients (mean age: 61.58 ± 12.41 years; male: 56.33%) were enrolled in this prospective, multicenter, observational study conducted across 137 hospitals in South Korea. Patients were treated with one of six QFDC regimens, which combined losartan (50 or 100 mg), amlodipine (5 mg), rosuvastatin (5 or 10 or 20 mg), and ezetimibe (10 mg). The primary endpoint was the percentage of patients who achieved a target blood pressure (BP) of 140/90 mmHg and low-density lipoprotein cholesterol (LDL-C) levels of 100 mg/dL 12 weeks post-treatment. Results Among the 1,965 eligible patients in the efficacy analysis set, 73.15% (95% confidence interval CI 71.19–75.11) achieved the target BP after 12 weeks of QFDC therapy (Figure). Similarly, 71.11% (95% CI 68.33–73.89) reached the target LDL-C level. Additionally, 57.11% (95% CI 54.08–60.15) achieved both target BP and LDL-C levels. The mean changes from baseline to 12 weeks were -13.69 ± 17.04 mmHg for systolic BP and -37.55 ± 34.93 mg/dL for LDL-C (both p0.0001), with greater reductions noted in subgroups with higher baseline levels (BP ≥140/90 mmHg or LDL-C ≥100 mg/dL). In the safety analysis set of 2,150 patients, the overall rates of adverse events (AEs) and adverse drug reactions (ADRs) were 0.79% and 0.33%, respectively. No serious adverse events (SAEs) or serious adverse drug reactions (SADRs) were reported. Conclusions The L/A/R/E QFDC regimen is an effective and safe treatment option for patients with concurrent hypertension and dyslipidemia.Efficacy and Safety of QFDC therapy
Park et al. (Sat,) reported a other. Quadruple-drug SPC therapy achieved target BP in 73.15%, target LDL-C in 71.11%, and both targets in 57.11% after 12 weeks with low adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: